Glioblastoma multiforme y estudio de la resistencia a la quimioterapia mediada por transportadores ABC

• Claudia Quezada ^[1] ; Lilia Peigñan ^[1] ; Rodrigo Segura ^[2] ; Francisco Riquelme ^[2] ; Rómulo Melo ^[2] ; David Rojas Z ^[2] ; Freddy Ayach ^[2] ; Rody San Martín ^[1] ; Juan Guillermo Cárcamo ^[1]
  1. [1] Universidad Austral de Chile

     Universidad Austral de Chile

     Valdivia, Chile

     
  2. [2] Instituto de Neurocirugía Dr. Asenjo Servicio de Neurocirugía
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 139, Nº. 4, 2011, págs. 415-424
• Idioma: español
• Títulos paralelos:
  • Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme
• Enlaces
  • Texto completo
• Resumen

  • Background: Mortality rate is dramatically high in high grade brain tumors. The presence of multiple drug resistance transporters in glioblastoma multiforme, has contributed largely to the poor effcacy of targeted therapy against cancer in the central nervous system. Aim: To analyze the percentage of survival and mortality of patients with glioblastoma multiforme in a cohort of patients in Chile and to co-rrelate the chemo-resistance of these cells with the expression level of multiple drug resistance transporters. Materials and Methods: Eighteen biopsies of glioblastoma multiforme were obtained from patients at the Institute of Neurosurgery Dr. Asenjo (INCA). The tumor cells were obtained from primary cultures and the expression and activity of multiple drug resistance transporters was assessed by RT-PCR and immunohistochemistry. Population-based study was performed using the databases of the Department of Neurosurgery of INCA. Results: The number of patients with glioblastoma multiforme increased between 2007 and 2009, from 3.5% to 7.9% of total brain tumors. Mortality of these tumors is 90 % at three years. A high expression and activity of the multiple drugs resistance associated protein 1 (Mrp1) transporter was observed in primary cultures of biopsies. Conclusions: We propose that Mrp1 activity is responsible for the chemo-resistance of the glioblastoma multiforme and inhibition of this transporter could represent a plausible strategy for the treatment.